Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

ESTRADIOL

All products: not a benefit

Other products in the same Health Canada class (G03CA) — coverage varies; not interchangeable

  • Conjugated estrogens (Premarin): general benefit, Limited Use 398
  • B + estradiol (Vagifem 10): general benefit
  • Estradiol hemihydrate (Imvexxy): general benefit

Estrace · DIN 02225190 · 0.5mg · tablet

Listed, not a benefitDormant since 2023-12-15 · checked 2026-09-02 · What does dormant mean?
StatusListed, not a benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Estrace · DIN 02225190 Manufacturer: Acerus Pharmaceuticals Corporation; listing date 2016-04-29 Health Canada: Dormant since 2023-12-15 · brand PMS-ESTRADIOL · ATC G03CA03 ESTRADIOL · form Tablet · route Oral · ingredients ESTRADIOL 0.5 MG · company Pharmascience inc · schedule Prescription
Check this DIN again · Health Canada product record

Estrace: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=43420 · Verify on the e-Formulary ↗ (DIN 02225190)

Source record
DIN 02225190: Estrace Raw flags: notABenefit=Y, sec3=Y Item: 681600051; group id 733; item number 1797; lccId None; manufacturer id APC Source form: Tab; strength: 0.5mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02225190 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=43420
Interchangeable products
Lupin-Estradiol · DIN 02449048 · $0.1199
Shortage status: active shortage (reported 2019-07-01, last updated 2021-10-15) — report may be stale, confirm; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02225190
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Dormant since 2023-12-15 — choose a marketed DIN from the same-category list.
Other drugs in the same formulary class (68:16 Estrogens) and how they are covered

Matched class: 68:16 Estrogens

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: ESTRADIOL 17-B, ESTRADIOL HEMIHYDRATE, ESTRADIOL HEMIHYDRATE & PROGESTERONE Some products covered without a code (check the product listing): CONJUGATED ESTROGENS 68:16 Estrogens

CONJUGATED ESTROGENS

· 2 products · Limited Use, codes 398 (1), General benefit (1) · strengths: 0.625mg, 0.625mg/g · SR Tab, Vag Cr

ESTRADIOL 17-B

· 1 products · General benefit · strengths: 10mcg · Vag Tab with Applicator

ESTRADIOL HEMIHYDRATE

· 2 products · General benefit · strengths: 4mcg, 10mcg · Vag Insert

ESTRADIOL HEMIHYDRATE & PROGESTERONE

· 1 products · General benefit · strengths: 1mg & 100mg · Cap Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 68:16
Full class listing Related classes: 68:04 Corticosteroids, 68:08 Androgens, 68:12 Contraceptives, 68:20 Anti-Diabetic Agents, 68:24 Parathyroid Agents, 68:28 Pituitary Agents, 68:32 Progestogens and Oral Contraceptives, 68:36 Thyroids, 68:38 Anti-Thyroids Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1. Indications ESTRING (17 β-estradiol) is indicated for postmenopausal urogenital complaints due to estrogen deficiency such as feeling of dryness in the vagina (atrophic vaginitis) with or without pruritus vulvae, dyspareunia, dysuria and urinary urgency (atrophic mucosa in the urethra and trigonum). ESTRING should be prescribed with an appropriate dosage of a progestin for women with intact uteri, in order to prevent endometrial hyperplasia/carcinoma. The maximum recommended duration of continuous therapy is 2 years. 1.1. Pediatrics Pediatrics (< 18 years of age): No data are available to Health Canada; therefore, Health Canada has not authorized an indication for pediatric use. 1.2. Geriatrics Geriatrics (> 65 years of age): There have not been sufficient numbers of geriatric patients involved in studies utilizing ESTRING to determine whether those over 65 years of age differ from younger subjects in their response to ESTRING (See 7 Warnings and Precautions: Special Populations: Geriatrics). https://pdf.hres.ca/dpd_pm/00083118.PDF PM date: 2026-01-08 Source product: ESTRING; DIN 02168898; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Availability

Estrace · DIN 02225190 Shortage status: active shortage (reported 2019-07-01, last updated 2021-10-15) — report may be stale, confirm; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02225190

Check this DIN again
Health Canada: dormant products
Health Canada defines dormant products as: “products that were previously marketed in Canada but for which the manufacturer has suspended sale for period of at least 12 months.” (canada.ca, Sep 10, 2026 ↗)

Other review policies

For Estrace: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026